Contineum Therapeutics In... (CTNM)
Contineum Therapeutics Class A Common Stock Statistics
Share Statistics
Contineum Therapeutics Class A Common Stock has 25.87M shares outstanding. The number of shares has increased by 0.58% in one year.
| Shares Outstanding | 25.87M |
| Shares Change (YoY) | 0.58% |
| Shares Change (QoQ) | 0.36% |
| Owned by Institutions (%) | 80.91% |
| Shares Floating | 18.24M |
| Failed to Deliver (FTD) Shares | 951 |
| FTD / Avg. Volume | 1.57% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is -6.71 and the forward PE ratio is -1.52. Contineum Therapeutics Class A Common Stock's PEG ratio is 0.03.
| PE Ratio | -6.71 |
| Forward PE | -1.52 |
| PS Ratio | 0 |
| Forward PS | 4.8 |
| PB Ratio | 1.43 |
| P/FCF Ratio | -8.5 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Contineum Therapeutics Class A Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.69, with a Debt / Equity ratio of 0.03.
| Current Ratio | 20.69 |
| Quick Ratio | 20.69 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.03M |
| Employee Count | 41 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -70.35% in the last 52 weeks. The beta is 0.22, so Contineum Therapeutics Class A Common Stock's price volatility has been higher than the market average.
| Beta | 0.22 |
| 52-Week Price Change | -70.35% |
| 50-Day Moving Average | 6.77 |
| 200-Day Moving Average | 14.15 |
| Relative Strength Index (RSI) | 33.72 |
| Average Volume (20 Days) | 60.61K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -50.89M |
| Net Income | -42.26M |
| EBITDA | -50.89M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.18 |
Balance Sheet
The company has 21.94M in cash and 6.26M in debt, giving a net cash position of 15.68M.
| Cash & Cash Equivalents | 21.94M |
| Total Debt | 6.26M |
| Net Cash | 15.68M |
| Retained Earnings | -117.4M |
| Total Assets | 212.85M |
| Working Capital | 196.41M |
Cash Flow
In the last 12 months, operating cash flow was -32.84M and capital expenditures -514K, giving a free cash flow of -33.36M.
| Operating Cash Flow | -32.84M |
| Capital Expenditures | -514K |
| Free Cash Flow | -33.36M |
| FCF Per Share | -1.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CTNM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CTNM is $25, which is 444.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $25 |
| Price Target Difference | 444.7% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 3.87 |
| Piotroski F-Score | 3 |